Question Bank › Skeptical premise dismantled with receipts

Skeptical premise dismantled with receipts

Skeptical premise dismantled with receipts: the call's central doubt is answered by named, checkable current facts

Calls Tested
497
Answered YES
24
Hit Rate
4.8%
rare by design

Fate Therapeutics, Inc. (FATE) — this company's answers

NO on the Q3 2016 call 2016-11-07 C
The model's full reasoning — Q3 2016 call → NOWe need to determine if there is a specific doubt about the company that is live in the conversation, and whether management answers it with concrete, checkable facts from the recent period that run against it. Looking at the transcript, the main topics are: ProTmune clinical trial, FATE-NK100, ToleraCyte, iPSC platform. The analysts ask questions about the PROTECT study design, blinding, enrollment delays, and the potential for accelerated approval. There is a doubt about the trial's ability to support registration due to small sample size and the delay in enrollment. Management responds by explaining the rationale for blinding, the expansion of patient eligibility, and the expectation to initiate Phase 2 in Q1 2017. They also mention that they have seven sites open and are screening patients. However, the doubt is about whether the trial will be sufficient for approval. Management's answer is largely about the design and future plans, not about already realized facts that contradict the doubt. They mention that they have not discussed with FDA, but they believe the randomized controlled blinded study is supportive. They also mention that they have run simulations and think they have a chance to achieve statistical significance. This is more about projections and confidence than about concrete realized facts. Another doubt could be about the FATE-NK100 program, but the analysts ask about the bar for efficacy and the manufacturing. Management responds with preclinical data and plans, but again, these are not yet realized in the clinic. The doubt about the PROTECT study is that the trial may not be sufficient for approval due to small size and delay. Management's answer is that they have made protocol amendments to strengthen the study, but they have not yet produced results. The facts they cite are the protocol changes, the number of sites, and the expected initiation of Phase 2. These are not "already-occurring operating facts" that run against the doubt. They are plans and design changes. The doubt about the company's ability to get approval is not answered with concrete evidence like "we have already seen a reduction in GvHD in the first patients" or something like that. Instead, it's about the design and future expectations. Thus, the answer is NO.

← Back to the full FATE analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION — evident because analysts press it, or because management itself names it as what skeptics or the market believe — AND does management answer that specific doubt NOT with reassurance, plans, or argument, but with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD that run directly against it — concrete events, behaviors, or numbers already realized (customers renewed or expanded when expected to leave, demand that held or grew through the feared window, losses that narrowed from operations, the doubted product performing in real use, the feared dependency reduced by actual new business) — described specifically enough that a reader could later verify them, with management conveying that the same contrary evidence is continuing rather than a one-quarter fluke? Answer YES when both halves come through as one dynamic in the transcript, in whatever form fits the business: a genuine, company-specific standing doubt, and a rebuttal built from already-occurred operating facts that the doubt's holders could check. It strengthens a YES when management engages the doubt directly and calmly rather than deflecting, and when the facts offered are of a kind that will keep accruing. Answer NO if no company-specific doubt is visible — an ordinary healthy company fielding routine questions. NO if the doubt exists but the answer is chiefly confidence, vision, targets, or projections. NO if the period's evidence actually confirms the doubt and management is excusing it. NO if the contrary facts are one-time items (asset sales, settlements, financings) rather than operating substance. NO if the doubt is generic macro gloom not attached to this company. NO if the rebuttal facts are vague ('demand remains strong') without specific grounding. NO if the dynamic appears only in an analyst's characterization that management does not itself engage with substance. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
GL Globe Life Inc. Q1 2024 2024-04-23 F
MET MetLife, Inc. Q4 2023 2024-02-01 B+
SITM SiTime Corporation Q2 2023 2023-08-02 C+
PGRE Paramount Group, Inc. Q2 2023 2023-08-01 D
MBLY Mobileye Global Inc. Q2 2023 2023-07-28 B+
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
UAL United Airlines Holdings, Inc. Q4 2022 2023-01-18 B
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
LIN Linde plc Q2 2022 2022-07-28 B+
CME CME Group Inc. Q2 2022 2022-07-27 B
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
VVV Valvoline Inc. Q1 2022 2022-02-09 C+
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
AMC AMC Entertainment Holdings, Inc. Q2 2021 2021-08-09 D
ESRT Empire State Realty Trust, Inc. Q2 2021 2021-07-29 C+
T AT&T Inc. Q3 2018 2018-10-24 C+
AVT Avnet, Inc. Q2 2018 2018-01-25 B
PII Polaris Inc. Q3 2017 2017-10-24 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
CCOI Cogent Communications Holdings, Inc. Q2 2017 2017-08-03 B
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C
SAN Banco Santander, S.A. Q4 2015 2016-01-27 B

How the model reasoned

IPGP · Q3 2021 → YESThe question is very specific: Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION, and does management answer it with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD tha...YES The transcript shows a clear, company-specific doubt centered on China market softness and competitive pricing pressure, which analysts repeatedly press (e.g., on whether gross margins will hold, if diversification will offset the impact, and whether LightWELD can scale). Management directly engages this doubt by citing concrete, checkable facts from 2022: China revenue down only 7% while North America grew +55% and Europe +50%, gross margin expanded 100 bps to 49% driven by product mix and pricing discipline, and other China applications (EV battery, additive manufacturing, marking) remained robust.
CRBG · Q4 2022 → YESThe question is very specific: Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION, and does management answer it with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD tha...YES The transcript shows a clear, company-specific doubt about elevated fixed annuity surrenders in a rising-rate environment, which analysts press and management itself flags as expected for 2023.
GL · Q1 2024 → YESThe question is: Is there ONE IDENTIFIABLE DOUBT ABOUT THIS COMPANY THAT IS LIVE IN THE CONVERSATION, and does management answer that specific doubt with NAMED, CHECKABLE FACTS FROM THE RECENT PERIOD ...

More from the question bank

Profit machinery upgraded while volume stillNew chapter with early proofDemand has broadened across independent fronExternal validators convergingOperator fluency on fresh groundThe bottleneck is inside and being paid awayAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.